Halozyme reports positive results from insulin pump trial.
M2 PHARMA-October 31, 2011-Halozyme reports positive results from insulin pump trial(C)2011 M2 COMMUNICATIONS
31 October 2011 - US biopharmaceutical company Halozyme Therapeutics Inc (NASDAQ:HALO) has announced positive results from a study in patients with type 1 diabetes that receive their insulin therapy via pumps.
The randomised, double-blind, crossover phase Ib study was designed to determine insulin pharmacokinetics, glucodynamics, safety and tolerability of rHuPH20 (recombinant human hyaluronidase) as a single injection prior to the start of three days of NovoLog insulin aspart pump infusion therapy. The data demonstrated that pre-administration of 150 units of rHuPH20 (approximately 1.3 micrograms of enzyme) led to consistent insulin exposure over the infusion set life and superior glucose control following meals.
The study also evaluated safety and local tolerability of rHuPH20 over the course of 72 hours of inpatient pump delivery, following pre-administration of rHuPH20 through subcutaneous infusion. Compared to insulin aspart alone, pre-administration with rHuPH20 reduced the variability in insulin exposure and action profiles observed with continuous insulin infusion and provided a consistent ultrafast profile over three days of use.
Consistent with previous reports, rapid acting analogue insulin delivered by itself via subcutaneous infusion exhibited significant variability in both absorption and action over three days of infusion set use. In the test meal setting, the consistent ultrafast profile with pre-administration of rHuPH20 led to consistently reduced postprandial excursions.
((Comments on this story may be sent to firstname.lastname@example.org))